Goldman Sachs Group set a €114.00 ($132.56) price target on MorphoSys (ETR:MOR) in a research report sent to investors on Wednesday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. set a €120.00 ($139.53) target price on MorphoSys and gave the company a buy rating in a report on Wednesday. Berenberg Bank set a €150.00 ($174.42) target price on MorphoSys and gave the company a buy rating in a report on Monday, August 5th. Independent Research set a €96.00 ($111.63) target price on MorphoSys and gave the company a neutral rating in a report on Thursday, July 4th. Royal Bank of Canada set a €65.00 ($75.58) target price on MorphoSys and gave the company a sell rating in a report on Monday, June 24th. Finally, Deutsche Bank set a €133.00 ($154.65) target price on MorphoSys and gave the company a buy rating in a report on Thursday, July 18th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of €113.56 ($132.04).

ETR:MOR opened at €111.00 ($129.07) on Wednesday. The company has a market capitalization of $3.50 billion and a price-to-earnings ratio of -84.03. The company’s 50 day moving average is €96.61. MorphoSys has a 52 week low of €76.45 ($88.90) and a 52 week high of €114.60 ($133.26). The company has a debt-to-equity ratio of 8.61, a current ratio of 7.62 and a quick ratio of 7.40.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Read More: How Do Investors Open a Backdoor Roth IRA?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.